$NVCR insider trading
Over the last 12 months, NovoCure insiders reported no purchases and 20 sales totaling $3.3M across SEC Form 4 filings.
- Bought · 12m
- — 0 events
- Sold · 12m
- $3.3M 20 events
- Events · 12m
- 20 Form 4 filings, grouped
- Insiders · 12m
- 14 distinct reporters
- 10b5-1 share
- 0% of events, not dollars
All insider trades
Scroll the table sideways for price, value and marks.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Jun 4, 2026 | Leonard Frank XChief Executive Officer · O | ▼ Sale | 34,273 | $17.93 | $615K | -6.9% | — |
| Jun 2, 2026 | LEUNG GABRIELD | ▼ Sale | 2,945 | $15.77 | $46K | -3.2% | — |
| Jun 2, 2026 | Stafford KristinD | ▼ Sale | 2,945 | $15.77 | $46K | -20.6% | — |
| Jun 2, 2026 | Ocean Allyson JD | ▼ Sale | 2,945 | $15.77 | $46K | -20.6% | — |
| Jun 2, 2026 | Scannell Timothy JD | ▼ Sale | 2,945 | $15.77 | $46K | -17.1% | — |
| Jun 2, 2026 | HILLEMAN JERYL LD | ▼ Sale | 2,945 | $15.77 | $46K | -17.5% | — |
| Jun 2, 2026 | VERNON W ANTHONYD | ▼ Sale | 2,945 | $15.77 | $46K | -1.5% | — |
| Jun 2, 2026 | Hung DavidD | ▼ Sale | 2,945 | $15.77 | $46K | -12.6% | — |
| Mar 5, 2026 | Paravasthu MukundChief Operating Officer · O | ▼ Sale | 48,623 | $13.72 | $667K | -40% | 2 tranches |
| Mar 4, 2026 | Brackmann ChristophChief Financial Officer · O | ▼ Sale | 6,412 | $13.31 | $85K | -3.4% | — |
| Mar 4, 2026 | Leupin NicolasFormer Chief Medical Officer · O | ▼ Sale | 1,100 | $13.31 | $15K | -1.1% | — |
| Mar 4, 2026 | Puri Michal NathChief Human Resources Officer · O | ▼ Sale | 1,100 | $13.31 | $15K | -0.5% | — |
| Mar 4, 2026 | Leonard Frank XChief Executive Officer · O | ▼ Sale | 5,607 | $13.31 | $75K | -1.1% | — |
| Mar 4, 2026 | Weinberg UriChf Medical and Innovation Ofr · O | ▼ Sale | 6,412 | $13.31 | $85K | -2.3% | — |
| Mar 3, 2026 | DOYLE WILLIAM FExecutive Chairman · O·D | ▼ Sale | 71,887 | $12.98 | $933K | -18% | 2 tranches |
| Mar 2, 2026 | Paravasthu MukundChief Operating Officer · O | ▼ Sale | 1,963 | $13.63 | $27K | -2.5% | 2 tranches |
| Mar 2, 2026 | Leonard Frank XChief Executive Officer · O | ▼ Sale | 16,966 | $13.59 | $231K | -4.6% | 2 tranches |
| Mar 2, 2026 | Weinberg UriChf Medical and Innovation Ofr · O | ▼ Sale | 10,733 | $13.68 | $147K | -4.6% | 2 tranches |
| Feb 27, 2026 | Leupin NicolasFormer Chief Medical Officer · O | ▼ Sale | 1,029 | $13.66 | $14K | -1% | — |
| Feb 27, 2026 | Puri Michal NathChief Human Resources Officer · O | ▼ Sale | 1,441 | $13.66 | $20K | -0.9% | — |
| Sep 5, 2025 | Cordova AshleyChief Executive Officer · O | ▲ Buy | 81,550 | $12.22 | $997K | +22.9% | — |
Every $NVCR filing on this page is one API call away
The same Form 4 data over REST or MCP, already grouped into events with the plan flag and the dollar value read. A free key does 100 calls a day and needs no card. Prefer email? NovoCure filings can reach your inbox instead.
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. This page shows open-market activity: purchases (code P), sales (S) and dispositions back to the issuer (D). Scheduled compensation events such as stock grants and option exercises are also filed on Form 4 but carry no trading signal, so they are not shown and counts here can be lower than the raw EDGAR filing total. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $NVCR feed.